Compare CRSP & SIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | SIG |
|---|---|---|
| Founded | 2013 | 1950 |
| Country | Switzerland | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 2016 | 1997 |
| Metric | CRSP | SIG |
|---|---|---|
| Price | $56.82 | $93.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 7 |
| Target Price | $70.29 | ★ $111.14 |
| AVG Volume (30 Days) | ★ 1.4M | 938.0K |
| Earning Date | 05-05-2026 | 06-02-2026 |
| Dividend Yield | N/A | ★ 1.51% |
| EPS Growth | N/A | ★ 974.07 |
| EPS | N/A | ★ 7.08 |
| Revenue | $289,590,000.00 | ★ $6,247,100,000.00 |
| Revenue This Year | $743.50 | $1.36 |
| Revenue Next Year | $163.21 | $1.71 |
| P/E Ratio | ★ N/A | $13.11 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $33.03 | $52.14 |
| 52 Week High | $78.48 | $110.20 |
| Indicator | CRSP | SIG |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 57.33 |
| Support Level | $51.64 | $89.54 |
| Resistance Level | $60.63 | $95.10 |
| Average True Range (ATR) | 2.28 | 3.65 |
| MACD | 1.17 | 1.11 |
| Stochastic Oscillator | 94.14 | 93.89 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.